Literature DB >> 3935756

Activation of macrophage cytostatic and cytotoxic activity in vitro by liposomes containing a new lipophilic muramyl peptide derivative, MDP-L-alanyl-cholesterol (MTP-CHOL).

N C Phillips, M L Moras, L Chedid, J F Petit, J P Tenu, E Lederer, J M Bernard, P Lefrancier.   

Abstract

The ability of liposomes containing a new lipophilic muramyl peptide derivative, MDP-L-alanyl-cholesterol (MTP-CHOL), to induce peritoneal macrophage cytostatic activity and alveolar macrophage cytotoxic activity toward tumor cell targets in vitro was determined. MTP-CHOL was shown to be efficiently incorporated and subsequently retained in distearoylphosphatidylcholine/phosphatidylserine liposomes (DSPC/PS; 7:3 molar ratio), whereas hydrosoluble muramyl dipeptide (MDP) was rapidly lost due to leakage. Liposomes containing MTP-CHOL were able to stimulate mouse peritoneal macrophage cytostatic activity under conditions where free MDP was without effect. MTP-CHOL incorporated into liposomes was approximately eightfold more effective than liposomes containing entrapped MDP and 7,400-fold more effective than free MDP in inducing rat alveolar macrophage cytotoxic activity. These results provide evidence that the coupling of MDP to a lipophilic molecule, cholesterol, results in the formation of a viable liposome formulation that is a potent inducer of macrophage-mediated antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3935756

Source DB:  PubMed          Journal:  J Biol Response Mod        ISSN: 0732-6580


  7 in total

1.  Liposomal muramyl dipeptide therapy of experimental M5076 liver metastases in mice.

Authors:  N C Phillips; M S Tsao
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Inhibition of murine hepatic tumor growth by liposomes containing a lipophilic muramyl dipeptide.

Authors:  P Brodt; J Blore; N C Phillips; J S Munzer; J D Rioux
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Aerosol delivery of muramyl dipeptide to rodent lungs.

Authors:  R J Pettis; I Hall; D Costa; A J Hickey
Journal:  AAPS PharmSci       Date:  2000

4.  Activation of rat alveolar macrophages and protection against i.v. injected tumor cells by intratracheal administration of trehalose dimycolate.

Authors:  D Nolibe; R Masse; J P Tenu; M Lepoivre; J F Petit
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 5.  Kupffer cells and liver metastasis. Optimization and limitation of activation of tumoricidal activity.

Authors:  N C Phillips
Journal:  Cancer Metastasis Rev       Date:  1989-12       Impact factor: 9.264

Review 6.  Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy.

Authors:  Sanja Nabergoj; Irena Mlinarič-Raščan; Žiga Jakopin
Journal:  Med Res Rev       Date:  2018-12-13       Impact factor: 12.944

Review 7.  Translation of peptidoglycan metabolites into immunotherapeutics.

Authors:  Matthew E Griffin; Charles W Hespen; Yen-Chih Wang; Howard C Hang
Journal:  Clin Transl Immunology       Date:  2019-11-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.